Packaged Foods
Build Your Comparison
Side-by-side financial analysisStock Comparison
NCRA vs RELI vs JPM vs BAC vs GOCO
Revenue, margins, valuation, and 5-year total return — side by side.
Insurance - Brokers
Banks - Diversified
Banks - Diversified
Insurance - Brokers
NCRA vs RELI vs JPM vs BAC vs GOCO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Packaged Foods | Insurance - Brokers | Banks - Diversified | Banks - Diversified | Insurance - Brokers |
| Market Cap | $2M | $554K | $842.21B | $409.69B | $21M |
| Revenue (TTM) | $11M | $13M | $270.79B | $188.75B | $153M |
| Net Income (TTM) | $-4M | $-7M | $58.03B | $30.63B | $-290M |
| Gross Margin | 1.4% | -14.5% | 58.6% | 55.4% | 63.4% |
| Operating Margin | -25.2% | -66.3% | 27.7% | 18.5% | -297.4% |
| Forward P/E | — | — | 14.0x | 12.1x | — |
| Total Debt | $7M | $13M | $751.15B | $365.90B | $673M |
| Cash & Equiv. | $8M | $373K | $469.32B | $231.84B | $33M |
NCRA vs RELI vs JPM vs BAC vs GOCO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 21 | Jun 26 | Return |
|---|---|---|---|
| Nocera, Inc. (NCRA) | 100 | 3.7 | -96.3% |
| Reliance Global Gro… (RELI) | 100 | 0.0 | -100.0% |
| JPMorgan Chase & Co. (JPM) | 100 | 242.8 | +142.8% |
| Bank of America Cor… (BAC) | 100 | 181.6 | +81.6% |
| GoHealth, Inc. (GOCO) | 100 | 0.4 | -99.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NCRA vs RELI vs JPM vs BAC vs GOCO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NCRA plays a supporting role in this comparison — it may shine differently against other peers.
RELI lags the leaders in this set but could rank higher in a more targeted comparison.
JPM carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 14.6%, EPS growth 21.7%
- 435.6% 10Y total return vs BAC's 323.5%
- NIM 2.3% vs BAC's 1.8%
- 14.6% NII/revenue growth vs GOCO's -54.7%
BAC is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 12 yrs, beta 0.89, yield 2.4%
- Lower volatility, beta 0.89, current ratio 0.42x
- PEG 0.79 vs JPM's 1.08
- Beta 0.89, yield 2.4%, current ratio 0.42x
Among these 5 stocks, GOCO doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 14.6% NII/revenue growth vs GOCO's -54.7% | |
| Value | Better valuation composite | |
| Quality / Margins | 21.6% margin vs GOCO's -189.7% | |
| Stability / Safety | Beta 0.89 vs GOCO's 1.99 | |
| Dividends | 1.6% yield, 15-year raise streak, vs BAC's 2.4%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +24.4% vs GOCO's -87.7% | |
| Efficiency (ROA) | 1.3% ROA vs NCRA's -52.5%, ROIC 5.4% vs -70.0% |
NCRA vs RELI vs JPM vs BAC vs GOCO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NCRA vs RELI vs JPM vs BAC vs GOCO — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 2 of 6 categories
BAC leads 1 • NCRA leads 0 • RELI leads 0 • GOCO leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — RELI and JPM each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $270.8B annually — 23812.7x NCRA's $11M. JPM is the more profitable business, keeping 21.6% of every revenue dollar as net income compared to GOCO's -189.7%. On growth, RELI holds the edge at -27.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $11M | $13M | $270.8B | $188.8B | $153M |
| EBITDAEarnings before interest/tax | -$3M | -$7M | $81.3B | $36.6B | -$400M |
| Net IncomeAfter-tax profit | -$4M | -$7M | $58.0B | $30.6B | -$290M |
| Free Cash FlowCash after capex | -$3M | -$2M | -$119.7B | $12.6B | -$107M |
| Gross MarginGross profit ÷ Revenue | +1.4% | -14.5% | +58.6% | +55.4% | +63.4% |
| Operating MarginEBIT ÷ Revenue | -25.2% | -66.3% | +27.7% | +18.5% | -3.0% |
| Net MarginNet income ÷ Revenue | -34.0% | -53.4% | +21.6% | +16.2% | -189.7% |
| FCF MarginFCF ÷ Revenue | -26.9% | -18.1% | -15.5% | +6.7% | -70.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -49.8% | -27.5% | — | — | -94.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.9% | +70.1% | +16.0% | +18.3% | -3.5% |
Valuation Metrics
Evenly matched — RELI and BAC each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 14.1x trailing earnings, BAC trades at a 11% valuation discount to JPM's 15.8x P/E. Adjusting for growth (PEG ratio), BAC offers better value at 0.92x vs JPM's 1.22x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2M | $553,552 | $842.2B | $409.7B | $21M |
| Enterprise ValueMkt cap + debt − cash | $2M | $13M | $1.12T | $543.8B | $661M |
| Trailing P/EPrice ÷ TTM EPS | -0.84x | -0.03x | 15.82x | 14.09x | -0.04x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 14.03x | 12.07x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 1.22x | 0.92x | — |
| EV / EBITDAEnterprise value multiple | — | — | 13.54x | 14.85x | — |
| Price / SalesMarket cap ÷ Revenue | 0.22x | 0.04x | 3.11x | 2.17x | 0.06x |
| Price / BookPrice ÷ Book value/share | 1.09x | 0.08x | 2.61x | 1.34x | — |
| Price / FCFMarket cap ÷ FCF | — | — | — | 32.48x | — |
Profitability & Efficiency
JPM leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 16.1% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-5 for GOCO. BAC carries lower financial leverage with a 1.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to RELI's 4.35x. On the Piotroski fundamental quality scale (0–9), BAC scores 7/9 vs GOCO's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -132.0% | -181.4% | +16.1% | +10.1% | -4.6% |
| ROA (TTM)Return on assets | -52.5% | -41.3% | +1.3% | +0.9% | -27.3% |
| ROICReturn on invested capital | -70.0% | -32.0% | +5.4% | +3.2% | -14.5% |
| ROCEReturn on capital employed | -35.9% | -45.9% | +8.2% | +4.2% | -15.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 5 | 7 | 2 |
| Debt / EquityFinancial leverage | 3.31x | 4.35x | 2.18x | 1.21x | — |
| Net DebtTotal debt minus cash | -$697,307 | $13M | $281.8B | $134.1B | $640M |
| Cash & Equiv.Liquid assets | $8M | $372,695 | $469.3B | $231.8B | $33M |
| Total DebtShort + long-term debt | $7M | $13M | $751.1B | $365.9B | $673M |
| Interest CoverageEBIT ÷ Interest expense | — | -4.90x | 0.74x | 0.44x | -4.46x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $20,251 today (with dividends reinvested), compared to $3 for RELI. Over the past 12 months, BAC leads with a +24.4% total return vs GOCO's -87.7%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.0% vs RELI's -84.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -80.3% | -54.3% | -3.1% | -2.8% | -70.4% |
| 1-Year ReturnPast 12 months | -83.7% | -81.7% | +21.5% | +24.4% | -87.7% |
| 3-Year ReturnCumulative with dividends | -88.7% | -99.6% | +135.5% | +99.5% | -96.4% |
| 5-Year ReturnCumulative with dividends | -96.6% | -100.0% | +102.5% | +36.1% | -99.6% |
| 10-Year ReturnCumulative with dividends | -97.4% | -100.0% | +435.6% | +323.5% | -99.8% |
| CAGR (3Y)Annualised 3-year return | -51.6% | -84.8% | +33.0% | +25.9% | -67.1% |
Risk & Volatility
BAC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BAC is the less volatile stock with a 0.89 beta — it tends to amplify market swings less than GOCO's 1.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BAC currently trades 93.5% from its 52-week high vs RELI's 6.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 1.35x | 0.95x | 0.89x | 1.99x |
| 52-Week HighHighest price in past year | $2.40 | $3.55 | $337.25 | $57.55 | $7.12 |
| 52-Week LowLowest price in past year | $0.16 | $0.15 | $260.31 | $43.66 | $0.60 |
| % of 52W HighCurrent price vs 52-week peak | +7.0% | +6.9% | +92.6% | +93.5% | +10.0% |
| RSI (14)Momentum oscillator 0–100 | 40.8 | 42.9 | 58.4 | 65.4 | 39.4 |
| Avg Volume (50D)Average daily shares traded | 7.2M | 2.9M | 7.1M | 32.4M | 84K |
Analyst Outlook
Evenly matched — JPM and BAC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: JPM as "Buy", BAC as "Buy". Consensus price targets imply 13.6% upside for BAC (target: $61) vs 8.5% for JPM (target: $339). For income investors, BAC offers the higher dividend yield at 2.35% vs JPM's 1.64%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy | — |
| Price TargetConsensus 12-month target | — | — | $338.78 | $61.13 | — |
| # AnalystsCovering analysts | — | — | 61 | 54 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.6% | +2.4% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 15 | 12 | 2 |
| Dividend / ShareAnnual DPS | — | — | $5.13 | $1.27 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.4% | +5.2% | +25.1% |
JPM leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). BAC leads in 1 (Risk & Volatility). 3 tied.
NCRA vs RELI vs JPM vs BAC vs GOCO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NCRA or RELI or JPM or BAC or GOCO a better buy right now?
For growth investors, JPMorgan Chase & Co.
(JPM) is the stronger pick with 14. 6% revenue growth year-over-year, versus -54. 7% for GoHealth, Inc. (GOCO). Bank of America Corporation (BAC) offers the better valuation at 14. 1x trailing P/E (12. 1x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NCRA or RELI or JPM or BAC or GOCO?
On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.
1x versus JPMorgan Chase & Co. at 15. 8x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Bank of America Corporation wins at 0. 79x versus JPMorgan Chase & Co. 's 1. 08x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NCRA or RELI or JPM or BAC or GOCO?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +102. 5%, compared to -100. 0% for Reliance Global Group, Inc. (RELI). Over 10 years, the gap is even starker: JPM returned +435. 6% versus RELI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NCRA or RELI or JPM or BAC or GOCO?
By beta (market sensitivity over 5 years), Bank of America Corporation (BAC) is the lower-risk stock at 0.
89β versus GoHealth, Inc. 's 1. 99β — meaning GOCO is approximately 123% more volatile than BAC relative to the S&P 500. On balance sheet safety, Bank of America Corporation (BAC) carries a lower debt/equity ratio of 121% versus 4% for Reliance Global Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NCRA or RELI or JPM or BAC or GOCO?
By revenue growth (latest reported year), JPMorgan Chase & Co.
(JPM) is pulling ahead at 14. 6% versus -54. 7% for GoHealth, Inc. (GOCO). On earnings-per-share growth, the picture is similar: JPMorgan Chase & Co. grew EPS 21. 7% year-over-year, compared to -29. 6% for GoHealth, Inc.. Over a 3-year CAGR, RELI leads at 13. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NCRA or RELI or JPM or BAC or GOCO?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 21. 6% net margin versus -71. 1% for GoHealth, Inc. — meaning it keeps 21. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 27. 7% versus -54. 8% for RELI. At the gross margin level — before operating expenses — GOCO leads at 73. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NCRA or RELI or JPM or BAC or GOCO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Bank of America Corporation (BAC) is the more undervalued stock at a PEG of 0. 79x versus JPMorgan Chase & Co. 's 1. 08x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 1x forward P/E versus 14. 0x for JPMorgan Chase & Co. — 2. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BAC: 13. 6% to $61. 13.
08Which pays a better dividend — NCRA or RELI or JPM or BAC or GOCO?
In this comparison, BAC (2.
4% yield), JPM (1. 6% yield) pay a dividend. NCRA, RELI, GOCO do not pay a meaningful dividend and should not be held primarily for income.
09Is NCRA or RELI or JPM or BAC or GOCO better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), 1. 6% yield, +435. 6% 10Y return). GoHealth, Inc. (GOCO) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +435. 6%, GOCO: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NCRA and RELI and JPM and BAC and GOCO?
These companies operate in different sectors (NCRA (Consumer Defensive) and RELI (Financial Services) and JPM (Financial Services) and BAC (Financial Services) and GOCO (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NCRA is a small-cap quality compounder stock; RELI is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; BAC is a large-cap deep-value stock; GOCO is a small-cap quality compounder stock. JPM, BAC pay a dividend while NCRA, RELI, GOCO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.